The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: phase 1. by Kanno, J et al.
Environmental Health Perspectives • VOLUME 109 | NUMBER 8 | August 2001 785
The OECD Program to Validate the Rat Uterotrophic Bioassay to Screen
Compounds for in Vivo Estrogenic Responses: Phase 1
Jun Kanno,1 Lesley Onyon,2 Joseph Haseman,3 Penelope Fenner-Crisp,4 John Ashby,5 and William Owens6
1National Institute of Health Sciences, Tokyo, Japan; 2Environment, Health and Safety Division, OECD, Paris, France; 3National Institute
of Environmental Health Sciences, Research Triangle Park, North Carolina, USA; 4U.S. Environmental Protection Agency, Washington,
DC, USA; 5Syngenta Central Toxicology Laboratory, Macclesﬁeld, Cheshire, UK; 6Procter & Gamble, Cincinnati, Ohio, USA
Concern has been raised that ambient envi-
ronmental levels of chemicals called environ-
mental estrogens may be causing adverse
effects in both humans and wildlife through
the interaction of these chemicals with the
endocrine system (1). Initial reviews of exist-
ing reports have noted limited evidence for
endocrine disruption in humans but have
noted several cases where local, high-level
exposures have produced effects in wildlife
(2–4). 
To address this concern, the Organisation
for Economic Co-operation and Development
(OECD) initiated a high-priority activity in
1997 to a) provide information on testing
and assessment activities, particularly at the
national regulatory level, and coordinate
these activities among member countries as
appropriate; b) revise existing guidelines and
develop new guidelines for screening and
testing potential endocrine disrupters; and c)
harmonize hazard and risk assessment
approaches internationally (5). The advan-
tage of the OECD activity is that it would
produce a set of internationally recognized
and harmonized screening and testing guide-
lines and strategies that would avoid duplica-
tion of testing resources, including animals.
The OECD activity is managed by the
Task Force on Endocrine Disrupters Testing
and Assessment (EDTA), the membership of
which includes experts nominated by OECD
member countries’ regulatory authorities,
international organizations, nongovernmen-
tal organizations, and industry associations.
The activity is part of the OECD Test
Guidelines Programme, so overall responsi-
bility of the work lies with the Working
Group of National Co-ordinators of the Test
Guidelines Programme (WNT).
The OECD conceptual framework iden-
tiﬁes short- and long-term assays of increasing
complexity and detail to gather information
on a chemical. The assays include a) struc-
tural activity relationships and in vitro assays
that would identify a chemical based on cer-
tain intrinsic characteristics (e.g., estrogen
receptor binding affinity); b) short-term in
vivo assays to demonstrate relevant activity in
the intact animal (e.g., the uterotrophic
assay); and c) long-term assays involving
exposure to the test substance at different
stages of the development of the animal (e.g.,
the two-generation reproductive assay). The
OECD strategy aims to develop these assays
as multipurpose tools rather than as a rigid
scheme. The purpose and use of a bioassay
could vary depending on the chemical sub-
stance and the available toxicological data on
that chemical. An early screen in one case
could become a means to determine a chemi-
cal’s mode of action in another (5).
In this article we focus on the OECD
validation program for an in vivo screen for
estrogenic activity. Historically, several can-
didate systems are available: a vaginal corniﬁ-
cation and keratinization response (6), a
water imbibition response of the uterus after
a single dose of the test compound (7), and a
uterine tissue weight increase after several
doses of the test compound (8–10). The
EDTA reached consensus to select the latter
assay, called the uterotrophic assay, for fur-
ther development and validation. The
uterotrophic response has been employed to
evaluate estrogenic activity using a number
of mammalian and avian species, although
primarily laboratory rodents. Because the rat
has become the preferred species for repro-
ductive and developmental toxicity testing,
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The Organisation for Economic Co-operation and Development has completed the ﬁrst phase of
an international validation program for the rodent uterotrophic bioassay. This uterotrophic bioas-
say is intended to identify the in vivo activity of compounds that are suspected agonists or antago-
nists of estrogen. This information could, for example, be used to help prioritize positive
compounds for further testing. Using draft protocols, we tested and compared two model sys-
tems, the immature female rat and the adult ovariectomized rat. Data from 19 participating labo-
ratories using a high-potency reference agonist, ethinyl estradiol (EE), and an antagonist, ZM
189,154, indicate no substantive performance differences between models. All laboratories and all
protocols successfully detected increases in uterine weights using EE in phase 1. These signiﬁcant
uterine weight increases were achieved under a variety of experimental conditions (e.g., strain,
diet, housing protocol, bedding, vehicle). For each protocol, there was generally good agreement
among laboratories with regard to the actual EE doses both in producing the first significant
increase in uterine weights and achieving the maximum uterine response. Furthermore, the Hill
equation appears to model the dose response satisfactorily and indicates general agreement based
on calculated effective dose (ED)10 and ED50 within and among laboratories. The feasibility of an
antagonist assay was also successfully demonstrated. Therefore, both models appear robust, repro-
ducible, and transferable across laboratories for high-potency estrogen agonists such as EE. For
the next phase of the OECD validation program, both models will be tested against a battery of
weak, partial estrogen agonists. Key words: endocrine disruption, estrogen, rat uterus,
uterotrophic. Environ Health Perspect 109:785–794 (2001). [Online 3 August 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p785-794kanno/abstract.htmlwe chose it as the test species for further
standardization and development of the
uterotrophic assay.
Two possible uterotrophic models are
based on the need to have a nonfunctional
hypothalamic-pituitary-gonadal axis to
ensure a sensitive and consistent uterine
response both to administered estrogens
alone and to administered antiestrogens in
combination with a reference estrogen. One
model uses the immature female before sig-
niﬁcant ovarian estrogen synthesis and regu-
lation by the hypothalamic-pituitary-gonadal
axis begins; the other model uses the ovariec-
tomized (OVX) adult female, removing the
primary source of estrogen synthesis. An
extensive comparison of these models across
several laboratories has never been per-
formed. However, data in the literature and
available data from laboratories participating
in the OECD program suggest that the two
models may be equivalent.
The objective of the OECD work on the
uterotrophic assay is to develop a new, vali-
dated test guideline and clearly define its
purpose. OECD member countries formally
agreed in a workshop held in Solna, Sweden,
in 1996 on the principles of validation and
criteria for the acceptability of new and
revised test guidelines (animal or nonani-
mal). These are now commonly known as
the “Solna principles and criteria” and follow
extensive work by national and regional
authorities on the validation and acceptabil-
ity of alternative test methods, including def-
initions of key terms (11). Validation is
deﬁned as the process by which the reliability
and the relevance of a procedure are estab-
lished for a particular purpose. Reliability is
deﬁned as the reproducibility of results from
an assay within and between laboratories.
Relevance describes whether a test is mean-
ingful and useful for a particular purpose.
The Solna principles and criteria were origi-
nally developed by the European Centre for
the Validation of Alternative Methods
(ECVAM) and the U.S. Interagency
Coordinating Committee on the Validation
of Alternative Methods (ICCVAM) and can
be summarized as follows: a) the test method
rationale should be stated, including the sci-
entific need and regulatory purpose; b) the
relationship of the end point(s) determined
by the test method to the in vivo biologic
effect and to the toxicity of interest must be
stated; c) the limitations of a method must
be described (e.g., metabolic capability); d) a
detailed protocol must be readily available
with sufficient detail to enable the user to
adhere to it, including data analysis and
decision criteria; e) test methods and results
should be publicly available and should have
been subjected to independent scientific
review; f) intratest variability, repeatability,
and reproducibility of the test method
within and among laboratories should have
been demonstrated, including a description
of variability with time; g) the test method’s
performance must have been demonstrated
using a series of reference chemicals, prefer-
ably coded to exclude bias; h) the perfor-
mance of test methods should have been
evaluated in relation to existing relevant toxi-
city data; i) all data supporting the assess-
ment of the validity of the test methods
including the full data set collected in the
validation study should have undergone sci-
entiﬁc review; and j) these data should have
been obtained in accordance with the
OECD Principles of Good Laboratory
Practice (GLP) (11). In 1998, OECD mem-
ber countries reconfirmed their commit-
ments to these validation principles and
criteria and further clariﬁed that the process
of validation should allow for flexibility.
However, to be able to justify a certain ﬂexi-
bility, a transparent standard procedure
should be available that allows for the assess-
ment of the need for and extent of the
required level of validation (12).
A Validation Management Group on
behalf of the EDTA of the OECD Test
Guidelines Programme coordinates the
work on human health test methods. The
Validation Management Group is com-
posed of experts from eight member coun-
tries nominated for their expertise in
toxicology, test development and validation,
endocrinology, regulatory toxicology, and
biostatistics. Experts from ICCVAM and
from ECVAM also participate in the
Validation Management Group.
Overall Program Design and
Objectives
The work on the uterotrophic assay is being
performed in phases. Phase 1, now com-
pleted, was designed to test, reﬁne, and stan-
dardize the immature and the adult OVX rat
uterotrophic assays using a high-potency ref-
erence agonist compound and to provide
data on intra- and interlaboratory variability
with this reference compound. In addition,
the feasibility of using the protocol for
antagonist assays was explored using a refer-
ence antagonist. A detailed report of phase 1
of the validation work on the uterotrophic
assay, including the rationale for the design
of this phase, was submitted to the VMG for
final approval in March 2001 (13). At this
time, further progress on the antagonist por-
tion of the assay awaits synthesis of sufﬁcient
quantities of the reference pure antiestrogen.
Few pure antagonists such as ZM 189,154 are
known (14). Most known estrogen antago-
nists such as tamoxifen will also express low
levels of an agonist response and would com-
plicate data interpretation by responding as a
positive in both agonist and antagonist sec-
tions of the assay (15).
Phase 2, currently underway, is designed
to demonstrate the capability of both stan-
dardized protocols against a set of test com-
pounds comprising weak estrogen partial
agonists and a known negative. Phase 2 is
intended to demonstrate the repeatability
and variation within and among laboratories
for several compounds and over time. To
properly investigate intra- and interlabora-
tory variability, the doses to be used in phase
2 will be speciﬁed in all cases. Twenty labo-
ratories are participating in phase 2.
The need for additional work after phase
2 will depend on the outcome of phase 2.
The results of the uterotrophic assays along
with other relevant biologic and toxicologic
data that may exist on the chemicals of inter-
est will be evaluated to demonstrate the reli-
ability and relevance of the uterotrophic
screen for its intended use in detecting estro-
gen agonists in vivo.
Design of phase 1. The objectives of the
first phase of the OECD validation work
were to a) demonstrate, in immature and
adult OVX rats, the dose–response relation-
ship between uterine weight and a reference
estrogen using two possible routes of admin-
istration—oral gavage and subcutaneous
injection; b) investigate intra- and interlabo-
ratory variation and identify any appropriate
protocol reﬁnements; c) compare the perfor-
mance of the protocols; and d) demonstrate
the feasibility of the protocols to identify
potential antiestrogenic activity using a pure
estrogen antagonist. 
Currently, several protocols are in use for
the uterotrophic assay. Three principal vari-
ables govern their differences: species, age of
test animal, and route of administration. The
result is eight possible test protocols, each
having literature precedents for their use. The
literature was reviewed and decisions made
on the basis of scientiﬁc rationale and practi-
cal experience, given the intent to develop an
OECD test guideline that could be trans-
ferred easily to many laboratories. The rat
was chosen over the mouse because it is used
most often as the preferred rodent model in
toxicology testing paradigms for regulatory
purposes. All protocols developed had essen-
tially the same design and differed only in the
model used and route of administration. The
protocols using oral gavage in immature ani-
mals and subcutaneous injection in ovariec-
tomized animals each had large databases of
available historical information. The third
protocol, subcutaneous injection of imma-
ture rat, also had a large database of historical
information and was chosen as a link
between the other two. A fourth protocol,
extending the duration of exposure in
ovariectomized animals, was carried out by
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this parameter had any effect on the sensitiv-
ity of the assay. 
The design of phase 1 then consisted of
testing four protocols: Protocol A used the
immature female rat model, with adminis-
tration of doses by oral gavage for 3 days at
24-hr intervals followed by humane killing
24 hr after the last administration. Protocol
B also used the immature female rat model,
with dosing by subcutaneous injection for 3
days at 24-hr intervals followed by humane
killing 24 hr after the last administration.
Protocol C used the adult OVX rat model,
with administration by subcutaneous injec-
tion for 3 days at 24-hr intervals followed by
humane killing 24 hr after the last adminis-
tration. Protocol C´ also used the adult
OVX model and extended the subcutaneous
dosing to 7 days with humane killing 24 hr
after the last administration. 
The reference estrogen agonist was 17α -
ethinyl estradiol (EE; CAS no. 57-63-6), and
the reference estrogen antagonist was the
pure antagonist ZM 189,154 (ZM; CAS no.
101908-22-9). The same lot of each chemi-
cal was distributed from a central repository.
These chemicals were gifts of Schering
(Kenilworth, NJ, USA) and Astra-Zeneca
(Alderley Park, Cheshire, UK), respectively. 
The lead laboratory was the National
Institute of Health Sciences of Japan.
Nineteen laboratories from Denmark,
France, Germany, Japan, Korea, the
Netherlands, the United Kingdom, and the
United States participated in phase 1.
Sixteen laboratories from seven nations per-
formed protocol A, 12 laboratories from six
nations performed protocol B, nine labora-
tories from three nations performed protocol
C, and four laboratories from one nation
performed protocol C´.
Because the uterotrophic assay is
intended to be widely practiced, participat-
ing laboratories used their traditional rat
strain, diet, vehicle, and housing procedures.
Animals were to be acquired from standard
animal supply sources with general instruc-
tions on acclimation and housing (e.g.,
immature animals transported with litters
together accompanied by the dam or a foster
dam, or scheduled to arrive as a litter when
they are 17 days old; room temperature of
22 ± 3°C and a relative humidity 30–70%;
artiﬁcial lighting with a 12-hr light and 12-
hr dark cycle; feed and tap or ﬁltered drink-
ing water provided ad libitum). Each
laboratory recorded the specifics, and sam-
ples of vehicle and diet were retained.
Individual animals were uniquely identiﬁed
(e.g., by ear tags or tail tattoos), and each
group was coded (e.g., by a letter and a color
on housing cages). Both an untreated con-
trol and a vehicle control were included to
allow detection of any signiﬁcant contamina-
tion of the vehicle with phytoestrogen(s).
There have been reports both in the older
literature and more recently that particular
lots of diet, presumably through the pres-
ence of phytoestrogens, could inﬂuence the
baseline uterine weight (16–20). If signifi-
cant variations in the control and vehicle
control uterine weights were observed, the
contributions of strain, diet, and so on could
then be investigated further, if necessary, as
retained samples of diet and vehicle were
required. Details of these particulars are pro-
vided in Table 1.
All protocols were based on a group size
of six animals. The total amount for subcu-
taneous injection per rat per day did not
exceed 4 mL/kg, and the total amount for
oral gavage per rat per day did not exceed 5
mL/kg. Included were daily measurement of
animal body weights and adjustment of vol-
umes to maintain the speciﬁed dose of sub-
stance for the allotted period. Body weights
starting on the day of administration ranged
from 26 to 57 g across laboratories for the
immature animals and from 142 to 327 g
for the adult OVX animals.
The end points of interest were the wet
and blotted uterine weights. The uterine
weight increase is a fundamental response of
the female to sufﬁcient exposure to estrogen
agonists. The response begins with the essen-
tial interaction of the estrogen with a high-
afﬁnity receptor in uterine tissues that initiates
a series of responses culminating in the uter-
ine weight increase. The weight increase is a
combination of water imbibition in the tissue
and the uterine lumina and a hypertrophic
response of the uterine tissues. The estrous
cycle in the rat is 4–5 days, so the 3-day
administration of a test compound is similar
to the response time to endogenous estrogen
surges in the intact animal that stimulate the
uterine tissue. Thus, estrogen agonists can be
identiﬁed by a statistically signiﬁcant increase
in uterine weight in treated versus untreated
or vehicle control animals. In addition, estro-
gen antagonists can be identiﬁed by blocking
or reducing the uterine weight increase of a
reference agonist when both are simultane-
ously administered. The estrogen speciﬁcity
of the uterine weight increase or decrease can
be veriﬁed, if necessary, by histologic exami-
nation of the uterus and the vagina (18,21).
Historically, most published uterotrophic
results have described uterine weights after
careful blotting of the uterus after its wall was
nicked or split to allow the luminal contents to
drain out. The rationale given for measuring
blotted uterine weight usually is that the wet
weights are more variable, and the variability
is increased by the possible loss of luminal
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Table 1. Rat strains, vehicle, animal diets, cage bedding, and housing used by participating laboratories.
Laboratory Rat strain Vehicle used Animal diet Cage bedding No. per cage
1 SD Crj CD(SD) IGS Corn oil CRF-1 PD, Oriental Yeast Co., Ltd., Japan None 3
2 SD Crj:CD(SD) IGS Corn oil CRF-1 PD, Oriental Yeast Co., Ltd., Japan None 2
3 SD Crj:CD(SD) IGS Sesame oil MF PD, Oriental Yeast Co., Ltd., Japan Autoclaved hardwood 3
4 Wistar Rj WI (SpF) Han Olive oil GKD, Provimi Kliba SA, SW SNIFF (type 3/4) 3
5 SD CD(SD)IG SBR Corn oil PMI CRD, W.F. Fisher & Son, USA None 2
6 SD CD(SD)GS BR Corn oil AO4C PD, Usine d'Alimentation Rationelle, France Autoclaved sawdust 2
7 SD Crj:CD(SD) IGS Sesame oil CE2, CLEA, Japan None 3
8 SD Alpk ApfSD Peanut oil SDS RM1, Special Diet Services Ltd., UK Shredded paper 3
9 SD CD(SD) IGS Olive oil MF PD, Oriental Yeast Co., Ltd., Japan None 1
10 SD CRJ CD Corn oil Cheil CRC, Cheil Feed Co., Korea None 2
11 Jcl:Wistar Corn oil MF PD, Oriental Yeast Co., Ltd., Japan None 3
12 SD Crl CD(SD) IGS BR Corn oil PMI CRD 5002, Cincinnati Lab Supply, USA Ground corn cobs 3
13 Wistar HSB/CpbWU Corn oil Altromin 1324, Altromin GmbH, Germany Low-dust wood granules 3
14 SD ICO:OFA SD(IOPS) caw Corn oil AO4C CRC, Usine d'Alimentation Rationelle, France None 2
15 Wistar Crl (Wi) WU BR Corn oil SDS RM3, Special Diet Services Ltd., UK None 6
16 Wistar HsdCpd:Wu Peanut oil Altromin 1324 FORTI, Altromin GmbH, Germany Wood chip 3
17 Wistar (mol:Wistar/Han) Peanut oil Altromin 1324, Brogaarden, Denmark Tapvei 3
18 SD CRl CD Corn oil PM1 CRD, PMI Nutrition International, USA Autoclaved elm tree 3
19 SD Hsd Corn oil SDS RM1 (E) SQC, Special Diet Services Ltd., UK None 3
Abbreviations: CRC, Certiﬁed Rodent Chow; CRD, Certiﬁed Rodent Diet; CRF, Certiﬁed Rodent Formula; GKD, Ground Klieba Diet; MF, Maintenance Formula; PD, pelleted diet; PMI, Purina
Mills, Inc.; RM, rat and mouse; SD, Sprague-Dawley; SDS, special diet services. ﬂuid during dissection and tissue handling.
For test optimization and validation, it was
decided to include both wet and blotted
uterine weights and to establish their vari-
ability in the models among different labo-
ratories using standardized procedures. The
uterine nicking and blotting technique was
adopted in all protocols. Both wet and blot-
ted weights were recorded to the nearest 0.1
mg in all protocols. Because several labora-
tories were performing the assay for the ﬁrst
time, and to standardize procedures, a
videotape of procedures for ovariectomy
and uterine dissection and preparation was
prepared and distributed to the participat-
ing laboratories.
Precaution was taken to specify the age
of the animals so that treatment could com-
mence at 19–20 days of age (day of birth
counted as day 1) and to limit body weight
variability. Limiting the weight variability
was thought essential to limit the chances of
older animals being inadvertently included
in the study. Older animals could enter
puberty, leading to an increase in control
uterine weight and thereby adding to the
variability of the results (19,22). For the
adult OVX animals, ovariectomy occurred
at 6 weeks of age or later, with a minimum
period of 1 week after surgery before
administration of the reference compounds.
In all protocols, groups were randomized
according to body weight.
The doses of EE and ZM administered
were speciﬁed to ensure that results could be
statistically compared. For EE, a series of
seven doses in half-log steps from 0.01 to 10
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Table 2. Number of laboratories observing a low-
est observed effect level (LOEL) at a given EE dos-
ing based on the first observed significant (p <
0.05) increase in uterine weight.
Dose of EE (µg/kg/day)
Protocol 0.03 0.1 0.3 1.0 3.0
Wet weight
A0 0 4 1 1 1
B1 3 8 0 0
C0 2 6 1 0
C´ 0 3 1 0 0
Blotted weight
A0 0 4 1 2 0
B2 3 7 0 0
C0 2 6 1 0
C´ 0 3 1 0 0
Table 3. Uterine and body weight data of the ﬁve highest EE doses (µg/kg/day) for protocol A.
Vehicle 0.1 0.3 1.0 3.0 10.0
Laboratory, measurement Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
1 Wet uterine weight (mg) 24.52 5.53 24.43 1.35 30.33 7.69 54.37* 14.25 113.62* 29.26 179.98* 40.94
Blotted uterine weight (mg) 23.28 5.58 23.25 1.08 29.12 7.71 52.65* 13.96 93.05* 12.82 116.40* 16.66
Body weight (g) 58.92 3.48 57.78 2.95 59.13 3.54 58.62 3.34 59.78 1.33 56.15 3.45
2 Wet uterine weight (mg) 32.02 2.77 31.22 1.92 42.52* 9.49 78.07* 24.25 153.25* 40.67 273.47* 46.83
Blotted uterine weight (mg) 31.45 3.00 30.57 1.89 41.23* 9.60 74.70* 21.81 117.18* 19.61 142.35* 13.11
Body weight (g) 58.75 5.19 57.88 2.80 58.07 4.16 59.02 3.85 58.97 3.20 55.87 1.86
3 Wet uterine weight (mg) 34.28 7.34 34.53 2.40 36.63 3.29 63.67* 9.61 137.17* 27.70 194.32* 49.75
Blotted uterine weight (mg) 32.50 6.75 32.92 2.44 34.38 3.12 60.28* 9.27 108.85* 13.60 125.68* 14.05
Body weight (g) 58.67 4.22 58.95 2.99 57.10 1.55 59.40 2.39 57.78 1.06 56.75 4.08
4 Wet uterine weight (mg) 24.33 1.21 27.83 4.22 23.00 2.45 29.50* 3.62 112.33* 19.13 157.33* 38.96
Blotted uterine weight (mg) 23.83 1.60 25.83 3.06 22.17 2.32 28.33* 3.08 92.50* 7.42 108.67* 13.22
Body weight (g) 57.55 4.90 54.90 2.10 57.97 2.91 58.23 2.76 55.90 1.69 54.28 1.34
5 Wet uterine weight (mg) 41.22 9.40 44.36 6.45 51.70 11.80 57.65* 9.59 132.20* 34.76 201.72* 5.51
Blotted uterine weight (mg) 38.78 8.06 41.30 6.08 47.12 12.23 55.75* 9.33 113.85* 23.58 139.10* 9.72
Body weight (g) 55.23 4.11 56.67 4.50 56.20 2.81 56.68 3.05 57.95 3.81 55.22 3.83
6 Wet uterine weight (mg) 42.25 8.04 42.51 8.45 48.04 15.78 64.90* 5.01 108.66* 19.58 179.38* 32.27
Blotted uterine weight (mg) 41.22 7.93 41.16 7.91 46.39 15.07 63.45* 5.34 100.78* 12.33 141.04* 17.69
Body weight (g) 55.15 4.01 56.68 5.43 56.13 6.52 56.27 4.84 54.05 6.18 55.68 5.25
7 Wet uterine weight (mg) 30.08 2.72 30.37 3.75 30.23 1.20 66.52* 20.70 104.82* 12.29 167.32* 28.54
Blotted uterine weight (mg) 28.58 3.11 29.57 3.66 28.80 1.95 63.77* 19.88 95.67* 7.86 124.60* 14.66
Body weight (g) 54.48 3.78 54.32 2.53 54.80 3.10 54.78 2.21 53.40 3.32 55.03 2.02
8 Wet uterine weight (mg) 32.68 8.02 31.43 6.95 38.28 10.70 65.70* 25.44 110.20* 26.57 162.58* 42.00
Blotted uterine weight (mg) 30.27 8.59 29.42 6.55 35.48 9.98 59.95* 21.08 94.80* 19.96 117.12* 15.46
Body weight (g) 53.88 5.41 54.68 4.67 55.75 4.71 55.57 6.93 55.45 6.32 55.07 6.09
9 Wet uterine weight (mg) 35.22 4.24 35.93 2.16 36.20 4.64 55.88* 10.15 120.58* 22.99 202.18* 30.11
Blotted uterine weight (mg) 34.28 4.12 35.02 2.67 35.33 4.90 54.75* 10.20 102.53* 12.57 133.48* 12.97
Body weight (g) 51.63 2.75 51.53 3.44 52.83 3.23 51.58 2.28 51.10 3.04 51.80 2.49
10 Wet uterine weight (mg) 44.70 13.01 58.17 12.02 57.43* 4.40 77.87* 8.29 148.53* 36.30 195.72* 23.42
Blotted uterine weight (mg) 42.27 12.72 55.72 12.25 55.27* 4.31 74.92* 7.96 119.83* 27.52 120.88* 16.47
Body weight (g) 49.43 6.82 50.42 3.12 46.92 5.12 47.58 4.02 51.72 3.06 47.50 3.66
11 Wet uterine weight (mg) 36.85 3.21 36.60 3.73 55.60* 6.17 97.93* 5.91 204.47* 31.87 190.55* 42.60
Blotted uterine weight (mg) 33.47 2.74 33.50 3.57 52.12* 6.33 86.87* 3.44 129.10* 6.28 127.90* 8.93
Body weight (g) 48.28 1.86 49.20 2.62 48.52 2.61 48.18 3.06 47.37 2.79 48.00 2.83
12 Wet uterine weight (mg) 31.65 11.97 41.00 13.61 37.23 6.57 57.70* 13.04 117.25* 19.37 174.73* 28.47
Blotted uterine weight (mg) 29.27 9.88 38.67 13.79 28.78 8.74 53.63* 9.36 95.33* 5.04 119.47* 9.47
Body weight (g) 47.23 3.92 48.05 3.81 46.95 3.35 48.38 4.11 46.98 3.20 46.72 3.61
13 Wet uterine weight (mg) 37.33 5.68 37.33 5.09 34.33 5.24 44.83 4.36 83.83* 9.30 241.17* 31.54
Blotted uterine weight (mg) 34.83 5.78 36.00 4.29 32.83 5.60 42.33* 3.98 76.17* 4.17 134.33* 12.24
Body weight (g) 42.60 3.66 40.13 1.76 39.48 3.10 37.97 5.91 38.73 2.60 41.42 4.65
14 Wet uterine weight (mg) 21.23 2.17 21.53 3.59 36.23* 6.74 67.55* 14.69 109.92* 31.44 119.73* 48.74
Blotted uterine weight (mg) 17.63 2.32 18.65 3.91 32.35* 6.92 54.62* 5.59 69.20* 10.95 78.07* 9.51
Body weight (g) 41.17 2.68 42.88 2.06 42.00 2.01 44.10 3.72 40.15 5.55 43.18 5.66
15 Wet uterine weight (mg) 32.00 4.74 36.83 7.39 35.17 6.97 77.00* 15.17 173.00* 38.33 202.67* 59.35
Blotted uterine weight (mg) 25.80 5.50 26.00 7.04 29.33 4.41 65.50* 12.82 108.00* 7.48 126.00* 13.61
Body weight (g) 38.78 1.49 39.73 1.72 38.32 1.48 37.42 1.34 38.33 1.73 39.83 2.70
16 Wet uterine weight (mg) 35.73 10.14 29.03 5.45 44.18 19.93 93.83* 24.71 213.73* 34.79 233.55* 60.90
Blotted uterine weight (mg) 32.63 9.47 26.20 4.74 40.67 18.57 80.47* 18.34 131.58* 5.62 118.07* 18.67
Body weight (g) 33.02 1.23 34.95 3.38 35.02 4.01 33.05 2.82 33.17 2.28 37.20* 2.07
*p < 0.05 versus vehicle.µg/kg/day was speciﬁed for both oral gavage
and subcutaneous administration. For the
ZM, the reference EE dose speciﬁed was, in
protocol A, 3.0 µg/kg/day, and in protocols
B, C, and C´, 0.3 µg/kg/day with two ZM
doses, 0.1 and 1.0 µg/kg/day to be coadmin-
istered. EE and ZM 189,154 were dissolved
in a minimal amount of 95% ethanol and
diluted to the ﬁnal working concentration in
the test vehicle (e.g., corn, arachis, sesame,
or olive oil). For the ZM189,154, gentle
heating up to 60°C was needed for dissolu-
tion. Other protocol details are omitted here
for brevity.
Participating laboratories submitted the
raw data for central, independent statistical
analysis. The ability to detect increased uter-
ine weights was evaluated by an analysis of
variance (ANOVA) approach, including
body weight as a covariable. A variance-stabi-
lizing logarithmic transformation was per-
formed before the data analysis. Dunnett’s
test was used for making pairwise compar-
isons of each dosed group to vehicle controls.
Dixon’s outlier test was used to detect possible
outliers, and Bartlett’s test was used to assess
homogeneity of variances. If signiﬁcant het-
erogeneity was detected, the nonparametric
Mann-Whitney U-test was used. For these
data, parametric and nonparametric analyses
produced similar results.
Results 
All participating laboratories conﬁrmed that
the protocol was straightforward to perform.
Suggested protocol refinements included
additional guidance to reduce organ weight
variation such as that caused by different
prosectors; improved procedures for control-
ling body weight (in immature animals) and
increasing the immature age for administra-
tion, because some laboratories encountered
weight loss in the early weanlings.
All laboratories and all protocols were
successful in detecting increases in uterine
weights in the higher dosed EE groups.
Within each protocol, there was good
agreement among laboratories in the
dose–response uterine weight increases for
the reference EE. This included the EE doses
identified as lowest observed effect levels
(LOELs)—that is, the doses at which signiﬁ-
cant increases in uterine weight were first
detected. The number of laboratories that
observed a LOEL at a given dose for each
protocol are summarized in Table 2. Blotted
weights showed statistical significance at
slightly lower EE concentrations than did
the wet uterine weights. For protocol A, sig-
nificance was generally first achieved at 1.0
µg/kg EE. The data for the wet and blotted
uterine weights as well as body weights for
the five highest dose groups are shown for
Protocols A, B, C, and C´ in Tables 3, 4, 5,
and 6, respectively. For protocols B and C,
significance was generally first achieved at
the next lower dose of 0.3 µg/kg EE. This
difference was expected the different route of
administration and previously published
data for EE (18). Three of the four labora-
tories carrying out protocol C´ first found
signiﬁcant increases in uterine weight at the
0.1 µg/kg EE dose. In the higher dose
groups, wet uterine weights were reduced
substantially in protocol C´ relative to proto-
col C, whereas the reverse tended to be true
for blotted weights. The reduced wet
weights in protocol C´ were apparently
caused by the reduction in luminal fluid
content between days 3 and 7.
The consistency of dose–response results
among laboratories was also evaluated: that
is, did laboratories consistently produce a
dose–response curve of approximately the
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Table 4. Uterine and body weight data of the ﬁve highest EE doses (µg/kg/day) for protocol B.
Vehicle 0.1 0.3 1.0 3.0 10.0
Laboratory, measurement Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
1 Wet uterine weight (mg) 29.28 3.17 31.03 4.86 71.95* 15.88 136.97* 18.14 255.22* 59.27 254.13* 39.02
Blotted uterine weight (mg) 28.27 3.03 29.85 4.75 69.22* 14.02 112.73* 10.93 140.33* 16.15 128.28* 4.56
Body weight (g) 61.48 3.05 60.00 2.47 60.45 4.41 59.32 3.77 60.28 3.89 57.37 2.77
2 Wet uterine weight (mg) 27.92 2.07 31.07 4.50 81.77* 15.97 182.00* 20.26 243.45* 47.28 293.08* 75.86
Blotted uterine weight (mg) 27.30 2.11 30.62 4.49 80.70* 15.93 131.77* 10.98 155.57* 11.64 162.68* 11.19
Body weight (g) 58.07 4.03 56.20 2.99 58.35 3.37 57.52 4.69 57.87 1.51 54.02 2.52
3 Wet uterine weight (mg) 31.98 3.30 35.12 4.19 79.28* 14.38 155.33* 22.93 267.58* 37.50 277.45* 48.56
Blotted uterine weight (mg) 30.72 3.45 32.82 4.02 75.37* 13.73 126.95* 15.08 149.67* 18.81 156.95* 7.98
Body weight (g) 57.85 3.57 56.70 4.08 55.98 3.49 55.62 4.64 55.03 4.63 56.12 1.56
7 Wet uterine weight (mg) 27.52 0.95 29.18 2.56 54.73* 18.31 157.57* 23.78 205.92* 27.19 220.48* 58.45
Blotted uterine weight (mg) 26.05 1.09 28.02 2.57 53.38* 17.97 125.95* 17.22 146.33* 7.28 159.30* 51.50a
Body weight (g) 53.08 2.37 52.32 3.12 53.03 3.51 51.98 3.49 52.77 3.48 51.76 2.19
8 Wet uterine weight (mg) 29.83 2.64 37.87# 7.20 64.57* 3.78 140.70* 24.61 175.58* 51.89 203.13* 53.79
Blotted uterine weight (mg) 27.20 2.79 34.62* 6.44 60.87* 3.69 112.50* 12.74 119.57* 15.91 125.05* 16.63
Body weight (g) 54.85 4.50 55.82 4.18 54.43 5.04 54.73 6.23 56.13 5.93 54.72 5.39
9 Wet uterine weight (mg) 32.62 3.97 34.03 3.53 56.68* 14.82 177.98* 43.27 259.13* 42.19 252.95* 37.30 
Blotted uterine weight (mg) 31.68 3.94 33.15 3.24 55.68* 14.63 131.67* 20.53 150.05* 18.88 146.67* 12.65
Body weight (g) 52.93 3.30 52.35 4.74 51.57 4.01 50.95 3.07 51.45 1.98 50.70 2.44
10 Wet uterine weight (mg) 39.20 5.88 96.72* 28.89 137.25* 32.79 226.13* 75.76 272.18* 23.16 256.43* 81.95
Blotted uterine weight (mg) 35.77 6.10 84.30* 17.90 113.67* 26.62 136.60* 19.85 141.83* 20.22 118.07* 21.04
Body weight (g) 48.00 2.95 47.32 5.30 46.08 6.87 46.85 4.03 46.62 4.31 45.53 5.84
11 Wet uterine weight (mg) 33.97 4.12 49.63* 8.87 91.15* 12.73 202.78* 50.74 278.76* 46.76 307.53* 46.78
Blotted uterine weight (mg) 29.67 4.36 46.53* 8.87 80.18* 8.80 130.85* 14.75 143.10* 12.86 141.27* 12.81
Body weight (g) 49.60 1.60 50.23 2.21 49.23 1.51 48.50 1.89 48.32 1.06 45.55* 2.29
12 Wet uterine weight (mg) 34.82 3.93 37.80 9.08 64.07* 21.85 118.38* 51.49 186.40* 70.98 249.40* 71.37
Blotted uterine weight (mg) 29.67 4.24 33.60 7.51 58.78* 14.70 96.63* 29.29 109.73* 18.98 133.95* 9.13
Body weight (g) 46.53 2.52 47.22 2.56 48.75 5.21 47.72 4.04 48.30 2.84 47.42 3.18
15 Wet uterine weight (mg) 36.50 7.84 37.67 7.03 78.50* 6.92 181.50* 55.88 238.67* 52.59 304.00* 75.92
Blotted uterine weight (mg) 25.83 7.19 27.33 6.02 60.17* 7.03 119.33* 17.27 138.33* 18.00 155.50* 9.16
Body weight (g) 42.93 1.21 41.30 2.55 41.80 2.24 42.33 1.90 42.18 2.84 42.97 1.65
17 Wet uterine weight (mg) 33.15 4.64 38.53 5.35 108.52* 29.15 240.32* 66.39 284.13* 42.98 242.93* 24.75
Blotted uterine weight (mg) 30.32 4.53 34.68 5.22 91.52* 17.00 132.98* 22.68 142.53* 14.40 130.60* 11.86
Body weight (g) 48.88 2.33 47.38 3.70 49.17 5.01 45.65 4.91 49.12 4.48 46.57 2.43
18 Wet uterine weight (mg) 21.72 2.89 28.13* 4.17 44.08* 6.18 142.92* 18.01 201.70* 24.29 257.75* 50.41
Blotted uterine weight (mg) 16.12 4.05 21.48* 5.13 33.70* 7.30 94.73* 7.82 106.90* 13.77 110.65* 11.24
Body weight (g) 38.32 4.35 39.47 2.29 36.87 2.66 40.35 2.17 38.10 3.60 41.50 3.46
aDenotes the presence of an outlier in the data. *p < 0.05 versus vehicle. #Signiﬁcant heterogeneity among groups; signiﬁcant (p < 0.05) versus vehicle controls by a Mann-Whitney U-test. same shape where the same percentage
increase in uterine weight, including the
maximal increase, occurred at equivalent
doses of the test compound? In protocol A, 8
of the 16 laboratories produced blotted uter-
ine weight responses that were statistically
consistent at all doses evaluated. In protocol
B, 5 of the 12 laboratories produced blotted
uterine weight responses that were statisti-
cally consistent at all doses evaluated. In pro-
tocol C, six of the nine laboratories produced
blotted uterine weight responses that were
statistically consistent. In protocol C´, all
four laboratories produced blotted uterine
weights that were statistically consistent (after
deleting one outlier). Dose–response results
are shown for all protocols in Figure 1.
The sensitivity of an assay can be deﬁned
in several ways. One approach is to identify
the lowest dose at which statistical signiﬁcance
is achieved (see Table 2). Protocol A
appeared less sensitive, as expected with the
oral route of administration for EE. The
data suggest no notable differences between
protocols B, C, or C´ in the dose first pro-
ducing statistical significance. Direct com-
parisons of performance should be based on
data from the same set of laboratories per-
forming both protocols. For example, eight
laboratories carried out both protocols B
and C. Seven laboratories achieved statisti-
cally significant increases at identical doses
for the wet uterine weight, and six achieved
statistically significant increases in blotted
uterine weight.
At the higher EE doses, there was a sig-
niﬁcant difference between the models in the
magnitude of the percentage uterine weight
increase over controls. For the 12 laborato-
ries carrying out protocol B, the range of
increased blotted uterine weights over
controls was 326–588% for the 1.0 µg/kg
EE dose and 370–663% for the 3.0 µg/kg
EE dose. For the nine laboratories carrying
out protocol C, the range for the increase in
blotted weights was 136–375% for the 1.0
µg/kg EE dose and 236–375% for the 3.0
µg/kg EE dose. The responses for all proto-
cols at 3 µg/kg EE dose are shown in Table
7. Protocol B, C, and C´ animals appeared
to have reached stable maximal responses in
the tested dose range. Protocol A animals
did not appear to have reached their stable
maximal response even at the 10 µg/kg EE
dose relative to the 3 µg/kg dose. 
Two procedures were performed to per-
mit meaningful comparisons of variability in
response. The first procedure was to log-
transform the uterine weight data. This was
followed by ANOVA for each laboratory
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Table 5. Uterine and body weight data of the ﬁve highest EE doses (µg/kg/day) for protocol C.
Vehicle 0.1 0.3 1.0 3.0 10.0
Laboratory, measurement Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
1 Wet uterine weight (mg) 104.35 13.53 114.48 4.82 197.22* 35.69 685.00* 167.66 1052.42* 43.53 1227.00* 262.581
Blotted uterine weight (mg) 102.35 12.85 112.22 4.42 190.45* 32.71 319.78* 57.47 373.72* 24.51 382.00* 35.21
Body weight (g) 210.42 9.35 203.53 11.68 201.53 9.68 202.00 12.18 194.67* 13.43 192.88* 10.87
2 Wet uterine weight (mg) 125.12 19.47 128.75 14.29 225.18* 32.82 697.13* 89.87 886.05* 104.73 1197.35* 134.96
Blotted uterine weight (mg) 120.82 18.43 123.47 12.71 217.48* 28.73 351.32* 27.51 384.72* 25.94 404.32* 44.63
Body weight (g) 216.55 17.91 213.38 13.73 210.38 8.00 208.08 7.98 201.08 11.29 193.58* 7.75
3 Wet uterine weight (mg) 121.58 6.49 151.13 55.68a 231.32* 21.61 656.50* 177.40 1001.52* 146.81 899.68* 322.24 
Blotted uterine weight (mg) 115.92 5.27 144.42 54.14a 213.95* 13.02 326.07* 60.22 378.37* 20.79 354.37* 54.84
Body weight (g) 235.20 12.80 228.10 11.00 228.92 12.77 218.93* 12.19 211.65* 10.90 212.38* 10.66
7 Wet uterine weight (mg) 123.28 12.15 133.80 12.01 225.77* 33.61 522.88* 319.22a 820.57* 175.01 906.77* 301.50
Blotted uterine weight (mg) 121.62 12.29 131.25 12.32 220.83* 32.25 317.52* 63.15 387.43* 34.40 391.67* 40.89
Body weight (g) 239.87 16.03 232.03 21.47 234.90 15.41 227.70 19.66 224.48 15.70 219.65 12.62
8 Wet uterine weight (mg) 83.73 10.42 110.17* 11.09 236.13* 25.52 406.43* 65.18 351.82* 53.27 391.27* 101.56
Blotted uterine weight (mg) 79.22 10.36 105.08* 10.33 211.13* 13.31 287.68* 23.33 262.20* 25.77 273.73* 42.91
Body weight (g) 295.00 30.19 291.00 36.13 293.33 31.48 287.83 29.55 280.33 20.57 278.83 24.32
9 Wet uterine weight (mg) 110.75 13.75 125.35 17.63 219.13* 30.01 717.53*  180.63 859.05* 164.29 866.62* 182.03 
Blotted uterine weight (mg) 108.47 13.23 123.60 16.68 211.37* 26.45 357.57* 47.52 353.82* 34.38 362.05* 41.95
Body weight (g) 224.02 13.55 217.57 6.40 219.57 9.47 211.02* 7.91 204.65* 5.75 200.22* 5.57
11 Wet uterine weight (mg) 86.00 19.07 118.42* 9.09 213.22* 12.32 613.82* 84.49 682.80* 86.85 714.18* 174.83
Blotted uterine weight (mg) 82.45 15.71 113.38* 10.13 191.23* 10.59 297.67* 15.99 307.60* 35.50 312.40* 43.05
Body weight (g) 169.62 7.14 169.13 6.61 165.48 7.09 162.73 4.68 159.03* 4.63 156.83* 5.62
18 Wet uterine weight (mg) 107.02 7.43 138.60 73.48a 241.33* 96.54 795.48* 225.16 930.65* 110.47 1104.27* 210.47
Blotted uterine weight (mg) 89.25 10.33 91.80 11.71 193.07* 64.32 334.95* 54.84 334.48* 44.55 366.20* 32.62
Body weight (g) 215.45 3.89 210.93 7.46 212.55 6.09 209.27 5.21 205.38* 4.88 195.52* 5.62
19 Wet uterine weight (mg) 104.17 10.76 85.33 8.78 108.33 13.47 140.50* 26.57 269.17* 78.70 588.33* 127.61
Blotted uterine weight (mg) 99.17 10.17 83.17 7.70 104.67 12.09 135.17* 24.19 234.17* 51.43 332.67* 27.34
Body weight (g) 290.63 12.84 298.60 11.89 301.75 7.84 287.18 27.35a 294.57 9.68 282.43 9.62
aDenotes the presence of an outlier in the data. *p < 0.05 versus vehicle.
Table 6. Uterine and body weight data of the ﬁve highest EE doses (µg/kg/day) for protocol C´.
Vehicle 0.1 0.3 1.0 3.0 10.0
Laboratory, measurement Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
1 Wet uterine weight (mg) 102.88 11.68 111.28 15.66 223.83* 35.02 395.62* 58.52 443.22* 95.81 685.95* 154.71
Blotted uterine weight (mg) 98.50 12.82 108.10 4.42 215.58* 35.90 347.95* 33.95 397.43* 48.61 422.18* 39.39
Body weight (g) 236.20 13.13 222.38 15.31 215.03* 12.42 205.43* 12.85 198.63* 11.29 201.32* 8.84
3 Wet uterine weight (mg) 106.58 6.49 132.02* 15.93 281.23* 43.07 367.55* 38.37 390.43* 18.59 516.85* 122.81
Blotted uterine weight (mg) 101.62 2.71 126.07* 15.46 267.58* 36.94 353.92* 35.94 376.05* 17.61 412.77* 38.11
Body weight (g) 256.80 8.18 242.13 12.84 243.25 8.23 223.75* 11.60 218.40* 10.20 210.52* 10.53
7 Wet uterine weight (mg) 103.62 15.39 190.40* 123.39a 267.23* 30.01 384.82* 61.81 412.50* 58.84 519.38* 45.55
Blotted uterine weight (mg) 100.87 15.16 164.32* 68.25a 259.18* 29.10 368.30* 49.85 393.82* 51.62 429.95* 36.53
Body weight (g) 252.73 15.65 238.77 11.93 240.83 16.64 227.30* 12.91 225.70* 13.92 221.45* 14.07
11 Wet uterine weight (mg) 92.83 10.14 127.90* 19.77 229.27* 18.18 395.58* 36.30 394.58* 33.26 444.58* 27.18
Blotted uterine weight (mg) 89.48 9.68 110.35* 20.69 217.85* 19.76 359.03* 31.43 368.37* 31.53 366.43* 15.03
Body weight (g) 202.63 4.45 196.32 6.70 192.00* 7.37 185.63* 3.29 176.27* 10.05 168.87* 6.23
aDenotes the presence of an outlier in the data. *p < 0.05 versus vehicle.and protocol, using body weight as a covari-
able. The error mean square resulting from
this analysis can be regarded as a measure of
intragroup variability, averaged over doses
and corrected for the possible influence of
body weight on the observed uterine weight
response. The second procedure was to cal-
culate the coefficient of variation (CV) in
uterine weight for each dosed group for each
laboratory within each protocol. The CVs
were averaged over doses to obtain a
representative value for each laboratory and
protocol. Each procedure produced similar
ﬁndings. The results for the second procedure
are summarized in Table 8. These analyses
revealed that a) within-group variability in
response was consistently less for blotted
weights than for wet weights; b) protocol A
tended to show more within-group variability
in both the wet and blotted measures of uter-
ine weights, which was not unexpected given
the oral route of administration; and c) the
adult OVX subcutaneous protocols (C and
C´) have slightly lower CVs than the imma-
ture animal subcutaneous protocol (B). Note
from Table 8 that some laboratories have con-
sistently different (lower or higher) CVs across
all protocols. This suggests an important role
for laboratory technique in controlling vari-
ability in both the wet and blotted uterine
weight response measurements.
Although body weights were controlled
tightly within a laboratory, animal body
weights varied widely in both the immature
and the adult OVX protocols from labora-
tory to laboratory. Yet despite these differ-
ences in body weights, generally similar
relative increases in both wet and blotted
uterine weight were observed at the various
laboratories for all of the protocols. High EE
doses reduced body weight in the adult OVX
protocols, but not in the immature animal
protocols. In protocols A and B, only one
laboratory recorded a signiﬁcantly (p < 0.05)
reduced body weight at the 10 µg/kg EE dose
relative to the vehicle, while one laboratory
recorded a signiﬁcant increase. In protocol C,
the 1.0, 3.0, and/or 10 µg/kg EE doses signif-
icantly reduced body weight relative to the
vehicle controls for six laboratories. In proto-
col C´, with extended dosing from 3 to 7
days, the four laboratories showed consis-
tently and significantly reduced body
weights in the high EE dose groups. This
weight loss is characteristic of potent estro-
gens such as EE or diethylstilbestrol. Loss of
body weight and adverse effects including
mortality require further consideration when
determining the doses to be tested in any
proposed OECD Test Guideline. These
issues will be considered further in dose
selection of test substances in phase 2 of the
validation program.
Body weight and uterine weight showed
no consistent correlation, with less than half
of the studies showing a signiﬁcant (p < 0.05)
correlation between these two variables.
Significant associations were found more
often in the immature animal protocols than
in the adult animal protocols. These ﬁndings,
coupled with the lack of significant body
weight effects in the immature animal proto-
cols, meant that the body weight adjustment
had relatively little impact on the evaluation
of uterine weights in these studies. 
In the ZM antagonism dose groups,
most laboratories found blotted uterine
weight decreases in the ZM/EE combination
groups that were statistically consistent, with
the magnitude of the reduction similar
across all laboratories. Interestingly, in all
eight laboratories that carried out both
protocols B and C, protocol B had a greater
percentage reduction in uterine weight at the
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Figure 1. Response of blotted uterine weight to doses of EE. (A) Participating laboratory results for protocol A using immature female rats, dosing by oral gavage for
3 consecutive days. (B) Participating laboratory results for protocol B using immature female rats, dosing by subcutaneous injection for 3 consecutive days. (C)
Participating laboratory results for protocol C using adult OVX rats, dosing by subcutaneous injection for 3 consecutive days. (D) Participating laboratory results for
protocol C´ using extended subcutaneous injection dosing to 7 days. In all cases, animals were humanely sacriﬁced 24 hr after the last dose administration. 
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However, there was no consistent difference
in sensitivity between protocols B and C for
the low-dose combination (0.1 mg/kg ZM +
0.3 µg/kg EE) group. One laboratory could
not demonstrate a decreased uterine weight
in the antagonist coadministration experi-
ments. This was apparently related to an
inability to induce a maximum uterine
response at an EE-alone dose so that a statis-
tically significant reduction could not be
observed (see Figure 1, protocol C, lab 19,
and Tables 7 and 10). 
The original data analysis plan included
a formal evaluation of whether the factors
that varied from laboratory to laboratory
could introduce variability in uterine weight
response. Factors that varied from laboratory
to laboratory included strain, diet, housing
protocol, bedding, and vehicle. However,
because of the overall consistency of the
uterine weight responses across laboratories
when these factors were reviewed (Table 1),
a formal analysis of this aspect was judged
unnecessary at this stage.
The analysis summarized in Table 9
illustrates the importance of minimizing the
coefﬁcient of variation in this type of study.
The power of detecting various increases in
uterine weight in the top dose group (by
Dunnett’s test) is analyzed as a function of
the magnitude of the response (from a 25%
to 40% increase in uterine weight), the
number of animals per group (6 or 10), and
the underlying CV (from 10.0 to 25.0). Six
animals per group appear to be sufﬁcient for
detecting a 25–35% increase in uterine
weight with reasonable power if the CV can
be kept relatively low (e.g., in the general
range of 10.0–15.0).
A widely used mathematical model, the
Hill equation model, generally provided a
good fit to the various data sets. The Hill
model was applied to the 41 individual
experiments. This permits an estimate of the
effective doses at various levels such as 10%,
50%, and 90% of the maximum, the ED10,
ED50, and ED90, respectively. The calcu-
lated results for the ED10 and the ED90 are
summarized in Table 10. The model calcula-
tions support the results previously reported
based on other types of statistical analyses.
For example, the estimated ED10 values in
protocols B, C, and C´ are lower than those
in protocol A, and no signiﬁcant difference
was found between the ED10 values from
protocols B, C, and C´. 
Discussion and Conclusions
All laboratories and all protocols were success-
ful in phase 1 of the OECD validation pro-
gram in detecting increases in uterine weights
using EE as the reference agonist. These sig-
nificant uterine weight increases were
achieved in both the immature and the adult
OVX models under a variety of different
experimental conditions besides route of
administration (e.g., strain, diet, housing pro-
tocol, bedding, vehicle). This suggests a cer-
tain robustness of the protocols, at least for
the reference EE. The consistency of the
results also suggests that no further speciﬁca-
tion of the strain of rat, diet, and so on is nec-
essary for this screening assay to detect potent
estrogen agonists. For each protocol, there
was generally good agreement among labora-
tories with regard to the actual EE doses that
produced increased uterine weights and the
maximum response observed. The shapes of
the uterine weight dose–response curves,
although similar for many labs, did show
some variation. The feasibility of an antago-
nist assay was also successfully demonstrated,
but in less detail because availability of the
ZM reference compound was limited. 
At this time, no substantive difference or
advantage in model—immature versus adult
OVX—has been found. Differences in
response to EE and ZM caused by the route
of administration were expected and did
occur. Nonetheless, these results reinforce
the sense of robustness of the protocols. For
example, there is a relatively consistent half-
log difference between subcutaneous and
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Table 7. Ratio of mean uterine weights in the 3.0 µg/kg/day EE group to that of the vehicle control.a
Wet weight Blotted weight
Laboratory  A B C C´ A  B C C´
1 463 872 1,009 431 400 496 365 403
2 479 872 708 NT 373 570 318 NT
3 400 837 824 366 335 487 326 370
4 462 NT NT NT 388 NT NT NT
5 321 NT NT NT 294 NT NT NT
6 257 NT NT NT 244 NT NT NT
7 348 748 666 398 335 562 319 390
8 337 589 420 NT 313 440 331 NT
9 342 794 776 NT 299 474 326 NT
10 332 694 NT NT 283 397 NT NT
11 555 821 794 425 386 482 373 412
12 370 535 NT NT 326 370 NT NT
13 225 NT NT NT 219 NT NT NT
14 518 NT NT NT 443 NT NT NT
15 541 654 NT NT 419 536 NT NT
16 598 NT NT NT 403 NT NT NT
17 NT 857 NT NT NT 470 NT NT
18 NT 929 870 NT NT 663 375 NT
19 NT NT 258 NT NT NT 236 NT
NT, not tested. 
aAll responses are signiﬁcant: p < 0.05 versus vehicle control (stated as a value of 100). 
Table 8. Comparison of coefﬁcients of variation (%) in uterine weights (averaged over dose groups within
a laboratory and protocol).
Wet weight Blotted weight
Laboratory A B C C´ A B C C´
1 18.9 16.9 13.4 19.4 16.5 14.0 11.1 16.6
2 15.5 15.4 11.2 NT 12.9 11.9 9.8 NT
3 17.1 12.4 15.9 10.5 14.2 10.7 12.0 9.0
4 14.9 NT NT NT 12.3 NT NT NT
5 18.1 NT NT NT 18.4 NT NT NT
6 18.7 NT NT NT 17.4 NT NT NT
7 15.9 14.2 18.6 16.9 15.4 14.4 11.7 14.5
8 23.8 15.4 14.1 NT 22.2 12.3 10.8 NT
9 14.9 16.1 16.6 NT 13.7 14.2 12.8 NT
10 20.9 22.3 NT NT 20.2 19.3 NT NT
11 14.6 14.4 12.8 10.4 10.8 12.2 10.8 10.3
12 21.8 25.8 NT NT 19.8 19.5 NT NT
13 16.0 NT NT NT 14.0 NT NT NT
14 20.0 NT NT NT 15.2 NT NT NT
15 21.1 19.1 NT NT 17.0 15.9 NT NT
16 26.3 NT NT NT 22.9 NT NT NT
17 NT 15.4 NT NT NT 13.9 NT NT
18 NT 15.3 24.8 NT NT 16.4 20.0 NT
19 NT NT 17.8 NT NT NT 16.0 NT
Overall meana 18.7 16.9 16.1 14.3 16.5 14.6* 12.8* 12.6*
SD 8.0 7.5 10.6 10.3 7.8 6.3 7.8 7.4
N 172 132 99 44 172 132 99 44
NT, not tested. 
aAveraged over doses and all laboratories. *Signiﬁcant (p < 0.05) versus protocol A by Dunnett's test (after adjusting for
differences due to dose and laboratory).oral gavage administration in observed
LOEL doses and the calculated ED10 doses
across protocols (see Tables 2 and 6 and
Figure 1). Group sizes of six animals appear
to be sufﬁcient to detect modest percentage
increases (25–35%) in uterine weight that
have been observed for weak partial estrogen
agonists (18,23). Both the wet and blotted
uterine weight end points were sensitive in all
protocols. The blotted weight was less vari-
able and, qualiﬁed by the use of high-potency
reference compounds, was first in a few
instances to indicate a statistically signiﬁcant
difference at lowest doses. Furthermore, the
Hill equation appears to model satisfactorily
the dose response to provide additional per-
spective on ED10, ED50, and maximal dose
responses within and among laboratories. 
Minor protocol reﬁnements were identi-
ﬁed. For example, protocol A was amended
to allow a wider variation in body weights so
that unnecessary animal use could be
avoided. A body weight variation of ± 20%
of the mean body weight (e.g., 35 g ± 7 g)
was proposed as sufﬁcient for the next phase
of the study. Randomization among the
groups will be maintained. Additionally, the
age range of immature animals at first
administration was expanded to 18–20 days.
Protocol C was amended to lengthen the
postoperative acclimatization period to 14
days. This allows further time for uterine
regression, the use of the vaginal smears to
confirm complete removal of the ovaries,
and greater ﬂexibility for laboratories in tim-
ing their experiments.
The current intent of the OECD pro-
gram is to proceed with both the immature
and the adult OVX models unless a substan-
tive difference in the ability to detect estro-
genic responses of the uterus is found. If
confirmed as equivalent, they may both be
considered for adoption as OECD Test
Guidelines. The OECD is now implement-
ing phase 2 of the program, which will entail
demonstration of the protocols using weak
estrogen partial agonists, such as genistein,
o,p´-DDT, methoxychlor, nonylphenol, and
bisphenol A. Phase 2 will continue to exam-
ine the performance of both immature and
adult OVX animal models.
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